We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Purpose-Built COVID-19 LIMS Solution Jump-Starts COVID-19 Testing and Research

By LabMedica International staff writers
Posted on 11 May 2020
A new purpose-built COVID-19 laboratory information management system (LIMS) solution can jump-start the ability of laboratories everywhere to enter biospecimens into a biobank and rapidly begin conducting COVID-19-related testing and research.

The new COVID-19 Biobanking Accelerator is built on the LabVantage Solutions, Inc.’s (Somerset, NJ, USA) industry-leading LIMS and Biobanking platforms used by clinical laboratories around the globe. Delivered as a comprehensive Software-As-A-Service (SaaS) solution, the LabVantage COVID-19 Biobanking Accelerator requires no infrastructure investment. Being pre-configured means minimal implementation time is needed with a go-live start possible in less than four weeks.

Illustration
Illustration

The LIMS Accelerator includes full biobanking capabilities and COVID-19 extraction and testing workflows with related master data for rapid use. It incorporates multiple protocols defined by the CDC for COVID-19 testing, and it can easily accommodate the addition of standard and customer-determined protocols for testing using a variety of approaches, such as RT-PCR, isothermal nucleic acid amplification and serology.

“Widespread laboratory testing is a critical component in the battle to control the coronavirus pandemic sweeping the globe. At LabVantage, we mobilized our decades of expertise to rapidly deliver a new purpose-built Biobanking LIMS to support COVID-19 testing and research,” said LabVantage CEO John Heiser. “It incorporates our deep knowledge of biobanking along with numerous features designed to make it easy for laboratories to acquire, implement and use the most powerful LIMS on the market for their COVID-19 testing. The LIMS Accelerator is also scalable, an important attribute as testing volumes escalate. Our outstanding service team stands ready to help customers begin using the package almost immediately. We are honored to have the opportunity to contribute to the laboratory testing and research that is critical to controlling and ultimately eliminating this devastating pandemic.”

Related Links:
LabVantage Solutions, Inc.


New
Gold Member
Pneumocystis Jirovecii Detection Kit
Pneumocystis Jirovecii Real Time RT-PCR Kit
Automated Blood Typing System
IH-500 NEXT
New
Free Human Prostate-Specific Antigen CLIA
LIAISON fPSA
New
Nuclear Matrix Protein 22 Test
NMP22 Test

Latest COVID-19 News

New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases

Long COVID Etiologies Found in Acute Infection Blood Samples

Novel Device Detects COVID-19 Antibodies in Five Minutes